Lv1
30 积分 2022-12-09 加入
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
1天前
待确认
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
1天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
Innovative antibody therapeutic development in China compared with the USA and Europe
1个月前
已完结
Development Strategy for Innovation System of Radiopharmaceuticals in China
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4个月前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
5个月前
已完结
The impact of external innovation on new drug approvals: A retrospective analysis
5个月前
已完结
The Withdrawal of Drugs for Commercial Reasons
5个月前
已完结
Monoclonal antibody based radiopharmaceuticals for imaging and therapy
6个月前
已完结
皖公网安备34019202002308
